UBS Group
NIVF

UBS Group’s NewGenIvf NIVF Stock Holding History

UBS Group’s Portfolio NIVF Stock Details NIVF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3K Buy
20,084
+20,017
+29,876% +$77.2K ﹤0.01% 7842
2026
Q1 		$452 Buy
+67
New +$812 ﹤0.01% 9889
2025
Q3 		– Hold
0
– -$363 – 11075
2025
Q2 		– Hold
0
– – – 9851
2024
Q4 		– Hold
0
– -$7.78K – 10519
2024
Q3 		– Hold
0
– – – 7877

Other funds holding NIVF

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's NIVF Position: Q2 2026 in Review

UBS Group increased its NewGenIvf (NIVF) stake by 29,876% in Q2 2026, buying an estimated $77.2K and bringing the position to 20,084 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7842.

UBS Group first reported a position in NIVF in Q1 2026 and has held it in 2 quarters since. 5 funds tracked by Wall St. Rank hold NIVF as of Q2 2026.

  • UBS Group held 20,084 shares of NewGenIvf worth $32.3K as of Q2 2026.
  • UBS Group bought 20,017 NewGenIvf shares in Q2 2026, an estimated $77.2K.
  • NewGenIvf made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7842 holding.
  • UBS Group first reported a position in NewGenIvf in Q1 2026 and has held it in 2 quarters since.
  • 5 funds tracked by Wall St. Rank held NewGenIvf as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.